KTTA

+ Watchlist + Portfolio

Pasithea Therapeutics Corp.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.49
52-Week Range: $0.28 – $2.06
Market Cap: $15.70M
P/E (TTM): —
EPS (TTM): -1.35
Dividend Yield: —

Advanced Metrics

Price/Book: 0.32
PEG Ratio: —
Return on Equity: -65.49%
Return on Assets: -36.00%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 26.25
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-12.64M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-29.29M

KTTA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Cost of Revenue	$113.19K	—	—	—
Gross Profit	$373.36K	—	—	—
Research & Development	$2.67M	$8.10M	$7.20M	$7.98M
Selling, General & Admin	$9.92M	$7.88M	$7.05M	$12.88M
Operating Expenses	$12.59M	$15.98M	$14.25M	$20.86M
Operating Income	-$12.59M	-$15.98M	-$14.25M	-$20.86M
EBITDA	-$12.58M	-$15.33M	-$13.60M	-$20.19M
Pretax Income	-$11.73M	-$15.51M	-$13.90M	-$20.43M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$13.94M	-$15.96M	-$13.90M	-$20.43M
Diluted EPS	-11.03	-13.01	-12.69	-2.91
Diluted Shares	1.26M	1.23M	1.10M	7.03M

KTTA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$33.09M	$16.33M	$6.92M	$55.16M
Receivables	$0.00	$40.50K	$0.00	—
Current Assets	$34.08M	$16.69M	$7.37M	$56.46M
Total Assets	$45.18M	$26.12M	$16.06M	$60.24M
Current Liabilities	$1.88M	$2.63M	$1.12M	$4.97M
Total Debt	$504.38K	$81.68K	$0.00	—
Total Liabilities	$2.68M	$2.72M	$1.28M	$5.02M
Retained Earnings	-$19.36M	-$35.32M	-$49.58M	-$70.01M
Shareholders' Equity	$42.50M	$23.40M	$14.78M	$55.22M
Working Capital	$32.20M	$14.06M	$6.25M	$51.49M

KTTA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.69M	-$13.43M	-$13.92M	-$15.21M
Capital Expenditure	-$107.10K	-$34.30K	—	—
Free Cash Flow	-$13.80M	-$13.46M	-$13.92M	-$15.21M
Depreciation & Amortisation	$5.09K	$648.45K	$649.03K	$662.59K
Stock-Based Compensation	$835.06K	$592.27K	$773.69K	$297.47K
Investing Cash Flow	-$2.93M	$399.01K	$0.00	$11.00K
Financing Cash Flow	-$3.21M	-$3.73M	$4.52M	$63.52M
Share Repurchases	-$3.21M	-$3.73M	$0.00	—
Net Change in Cash	-$19.82M	-$16.75M	-$9.41M	$48.32M

KTTA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$1.73M	$2.15M	$1.36M	$2.74M	$2.94M
Selling, General & Admin	$1.95M	$1.66M	$1.75M	$7.51M	$1.93M
Operating Expenses	$3.68M	$3.81M	$3.11M	$10.26M	$4.88M
Operating Income	-$3.68M	-$3.81M	-$3.11M	-$10.26M	-$4.88M
EBITDA	-$3.52M	-$3.65M	-$2.93M	-$10.10M	-$4.72M
Pretax Income	-$3.56M	-$3.72M	-$3.04M	-$10.11M	-$2.87M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$3.56M	-$3.72M	-$3.04M	-$10.11M	-$2.87M
Diluted EPS	-1.61	-0.66	-0.41	—	-0.12
Diluted Shares	2.21M	5.64M	7.44M	—	24.34M

KTTA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$5.34M	$7.22M	$4.12M	$55.16M	$50.40M
Current Assets	$6.12M	$8.64M	$5.53M	$56.46M	$52.73M
Total Assets	$14.66M	$17.01M	$13.63M	$60.24M	$56.35M
Current Liabilities	$1.59M	$1.74M	$1.38M	$4.97M	$1.49M
Total Liabilities	$1.68M	$1.83M	$1.42M	$5.02M	$1.54M
Retained Earnings	-$53.15M	-$56.86M	-$59.90M	-$70.01M	-$72.88M
Shareholders' Equity	$12.98M	$15.18M	$12.21M	$55.22M	$54.81M
Working Capital	$4.53M	$6.90M	$4.15M	$51.49M	$51.24M

KTTA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.06M	-$3.87M	-$2.89M	-$5.40M	-$4.79M
Free Cash Flow	-$3.06M	-$3.87M	-$2.89M	-$5.40M	-$4.79M
Depreciation & Amortisation	$162.36K	$161.09K	$181.59K	$157.54K	$157.54K
Stock-Based Compensation	$98.56K	$57.65K	$52.99K	$88.28K	$139.18K
Financing Cash Flow	$1.47M	$5.74M	-$116.14K	$56.42M	$750.00
Net Change in Cash	-$1.58M	$1.87M	-$3.01M	$51.04M	-$4.79M

Market Snapshot

About

Pasithea Therapeutics is a biotechnology company focused on developing treatments for psychiatric and neurological disorders. The company's pipeline includes therapies targeting depression, addiction, pain management, and other central nervous system conditions. Pasithea leverages novel mechanisms of action and drug delivery technologies to address significant unmet medical needs in mental health.